Results 91 to 100 of about 54,594 (319)

Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA‐Approved Bispecific Antibodies in Oncology

Clinical pharmacology and therapy
Bispecific antibodies, by enabling the targeting of more than one disease‐associated antigen or engaging immune effector cells, have both advantages and challenges compared with a combination of two different biological products.
KyoungSoo Lim, Xu Sue Zhu, Diansong Zhou, Song Ren, Alex Phipps   +4 more
semanticscholar   +1 more source

Core Fucosylation Represses SMURF1‐Dependent Degradation of CD47 to Promote Tumor Immune Evasion

Advanced Science, EarlyView.
FUT8‐mediated core fucosylation of CD47 at N111 blocks SMURF1 binding and reduces CD47 ubiquitination and degradation. Blocking N111 glycosylation reduces CD47 expression and promotes macrophage phagocytosis of tumor cells. Furthermore, ablating CD47 core fucosylation boosts CD103+ dendritic cells (DCs) infiltration, increases natural killer (NK) cell ...
Yuting Cao, Siyuan Chai, Mingyang Li, Xiaoming Chen, Jiating Hu, Bingyi Lin, Liming Wu, Wen Yi, Qiang Zhu   +8 more
wiley   +1 more source

Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure

Frontiers in Oncology
IntroductionAlthough checkpoint inhibitors (CPIs) have improved outcomes for patients with metastatic melanoma, those progressing on CPIs have limited therapeutic options.
Anna Spreafico, Eva Muñoz Couselo, Anja Irmisch, Juliana Bessa, George Au-Yeung, Oliver Bechter, Inge Marie Svane, Miguel F. Sanmamed, Miguel F. Sanmamed, Valentina Gambardella, Valentina Gambardella, Meredith McKean, Margaret Callahan, Reinhard Dummer, Christian Klein, Pablo Umaña, Nicole Justies, Florian Heil, Linda Fahrni, Eugenia Opolka-Hoffmann, Inja Waldhauer, Conrad Bleul, Roland F. Staack, Vaios Karanikas, Stephen Fowler   +24 more
doaj   +1 more source

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

TOPK Inhibition Promotes Anti‐Tumor Immunity Via eIF4F Complex Mediated STAT1 Translation in Gastric Cancer

Advanced Science, EarlyView.
This study identifies TOPK as a dual‐function target in gastric cancer: it drives tumor cell proliferation and migration, and under IFN‐γ stimulation, phosphorylates eIF4F complex component eIF4A1 to enhance STAT1 mRNA translation, thereby promoting PD‐L1/IDO1‐mediated tumor immunometabolic evasion.
Junbing Chen, Longtao Huangfu, Gangjian Wang, Xueying Wang, Huanbo Zhu, Qian Yao, Cong Chen, Xiaohuan Tang, Ting Guo, Biao Fan, Xingyang Liu, Qingda Li, Zining Liu, Ying Hu, Tianze Sun, Jiafu Ji, Xiaofang Xing   +16 more
wiley   +1 more source

Synthesis of Bispecific Conjugates by ADP‐Ribosyl Cyclases

Advanced Science, EarlyView.
Genetic fusion of a CD38 enzymatic domain to antibody scaffolds allows site‐specific conjugation of small‐molecule ligands. Using this approach, a PSMA ligand DUPA is conjugated with an anti‐human CD3 Fab antibody. The resulting bispecific anti‐CD3‐DUPA conjugate facilitates recruitment and activation of cytotoxic T cells against PSMA‐expressing ...
Sunny H. Kim, Arshad J. Ansari, Lei Zhang, Guoyun Kao, Thuc Oanh Hoang, Zeyu Zhang, Srinivasarao Singireddi, Benjamin B. Katz, Yong Zhang   +8 more
wiley   +1 more source

CD147/Basigin: From Integrative Molecular Hub to Translational Therapeutic Target

Advanced Science, EarlyView.
This review conceptualizes CD147 as a fundamental “Energy‐Structure Coupler,” physically bridging metabolic flux (via MCTs) with morphogenetic plasticity (via integrins/MMPs) to drive cancer, infection, and autoimmunity. Addressing the “specificity paradox” that limits current translation, the authors chart a strategic roadmap—spanning logic‐gated ...
Xiang‐Min Yang, Huijie Bian, Zhi‐Nan Chen   +2 more
wiley   +1 more source

Elranatamab in Heavily Pretreated Triple-class Refractory Multiple Myeloma: A Single-center Experience

Acta Haematologica Oncologica Turcica
Aim: This study aimed to assess the real-world performance of elranatamab in terms of its effectiveness, safety, and tolerability among patients diagnosed with triple-class refractory-multiple myeloma (TCR-MM) who have undergone extensive prior treatment.
Ant Uzay
doaj   +1 more source

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

The Role of Tumor Microenvironment and Targeted Therapy in Chronic Lymphocytic Leukemia

Current Issues in Molecular Biology
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. It is characterized by the clonal proliferation of mature B cells. The tumor microenvironment (TME) seems to play a crucial role in the survival and proliferation of tumor cells ...
Khalil Saleh, Ahmadreza Arbab, Nadine Khalife, Rita Khoury, Rebecca Ibrahim, Mohamad Ali Hachem, Cynthia Khalil, Cendrella Bou Orm, Joud Sawan, Geoffroy Lafarge, Nohad Masri, Zamzam Tikriti, Claude Chahine, Axel Le Cesne   +13 more
doaj   +1 more source